Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821256 | 1.00 | CYP2C9 (0.37) | CYP2C9MEN1KMT2AGAAKDM4E | |
| SCHEMBL8003058 | 0.88 | CYP2C9 (0.39) | CYP2C9MEN1KMT2AGAAKDM4E | |
| SCHEMBL17156385 | 0.88 | CYP2C9 (0.39) | CYP2C9MEN1KMT2AGAAKDM4E | |
| SCHEMBL6218422 | 0.82 | CYP2C9 (0.51) | CYP2C9MEN1KMT2AGAAKDM4E | |
| SCHEMBL6820603 | 0.82 | CYP2C9 (0.51) | CYP2C9MEN1KMT2AGAAKDM4E | |
| SCHEMBL2417580 | 0.77 | FFAR3 (0.33) | CYP2C9 | |
| SCHEMBL17156138 | 0.76 | CYP2C9 (0.37) | CYP2C9MEN1KMT2AGAAKDM4E | |
| SCHEMBL17156139 | 0.76 | CYP2C9 (0.37) | CYP2C9MEN1KMT2AGAAKDM4E | |
| SCHEMBL6015034 | 0.73 | CYP2C9 (0.55) | CYP2C9MEN1KMT2AGAAKDM4E | |
| SCHEMBL1325598 | 0.73 | CYP2C9 (0.55) | CYP2C9MEN1KMT2AGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102768-B1 | SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBERED HETEROCYCLIC RINGS | BAYER HEALTHCARE AG (DE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040224945-A1 | Novel substituted pyrazole derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-11 | — | — | US | disclosed |
| US-6743798-B1 | CARDIOVASCULAR DISORDERS; VASORELAXATION, INHIBITION OF PLATELET AGGREGATION, DECREASE IN BLOOD PRESSURE; STIMULATION OF SOLUBLE GUANYLATE CYCLASE AND AN INTRACELLULAR CGMP INCREASE | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1102768-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBERED HETEROCYCLIC RINGS | Bayer Aktiengesellschaft (DE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000006569-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBERED HETEROCYCLIC RINGS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224945-A1 | Novel substituted pyrazole derivatives | CYP11B2, CYP11B1, ADRB3 | CYP2C9 140/4885MEN1 2063/4885KMT2A 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.